- Home
- MOBX vs NRSN Comparison
MOBX vs NRSN Comparison
Compare MOBX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- NRSN
- Stock Information
- Founded
- MOBX 2020
- NRSN 2017
- Country
- MOBX United States
- NRSN Israel
- Employees
- MOBX N/A
- NRSN N/A
- Industry
- MOBX
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- NRSN Health Care
- Exchange
- MOBX Nasdaq
- NRSN Nasdaq
- Market Cap
- MOBX 41.3M
- NRSN 37.9M
- IPO Year
- MOBX N/A
- NRSN 2021
- Fundamental
- Price
- MOBX $0.69
- NRSN $1.79
- Analyst Decision
- MOBX
- NRSN Buy
- Analyst Count
- MOBX 0
- NRSN 2
- Target Price
- MOBX N/A
- NRSN $14.00
- AVG Volume (30 Days)
- MOBX 163.5K
- NRSN 293.7K
- Earning Date
- MOBX 05-15-2025
- NRSN 06-23-2025
- Dividend Yield
- MOBX N/A
- NRSN N/A
- EPS Growth
- MOBX N/A
- NRSN N/A
- EPS
- MOBX N/A
- NRSN N/A
- Revenue
- MOBX $10,692,000.00
- NRSN N/A
- Revenue This Year
- MOBX N/A
- NRSN N/A
- Revenue Next Year
- MOBX N/A
- NRSN N/A
- P/E Ratio
- MOBX N/A
- NRSN N/A
- Revenue Growth
- MOBX 450.28
- NRSN N/A
- 52 Week Low
- MOBX $0.55
- NRSN $0.51
- 52 Week High
- MOBX $2.47
- NRSN $1.77
- Technical
- Relative Strength Index (RSI)
- MOBX 43.78
- NRSN 73.44
- Support Level
- MOBX $0.67
- NRSN $1.65
- Resistance Level
- MOBX $0.73
- NRSN $1.77
- Average True Range (ATR)
- MOBX 0.07
- NRSN 0.14
- MACD
- MOBX -0.00
- NRSN 0.02
- Stochastic Oscillator
- MOBX 35.28
- NRSN 98.23
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.